Can Removing Amyloid Early Benefit Alzheimer's Disease Patients?
The amyloid cascade hypothesis of Alzheimer's disease suggests that aggregation of misfolded amyloid-β sets the stage for a feedback loop between chronic inflammation of brain tissue and tau aggregation. It is that second step that causes severe pathology and death, and once it is underway in earnest a patient's amyloid-β burden is of little relevance. This the explanation given for the lack of patient benefits resulting from the successful clearance of amyloid-β using forms of immunotherapy. The industry has now shifted to testing these treatments in patients at an earlier stage of Alzheimer's disease, and there are pr...
Source: Fight Aging! - November 16, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, November 13th 2023
This study investigated the correlation among muscle strength, working memory (WM), and cortical hemodynamics during the N-back task of memory performance, and further explored whether cortical hemodynamics during N-back task mediated the relationship between muscle strength and WM performance. We observed that muscle strength (particularly grip strength) predicted WM of older adults in this cross-sectional study, which validated our hypothesis and expanded on previous research findings. Studies demonstrated that grip strength predicted executive function decline in patients with mild cognitive impairment. Other cross-sect...
Source: Fight Aging! - November 12, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Mitochondrial Dysfunction is a Contributing Cause of T Cell Exhaustion
T cell exhaustion occurs in aging, but also in circumstances in which the adaptive immune system is constantly stimulated over time, such as in cases of persistent HIV infection, or the presence of solid tumors. An exhausted T cell has adopted a state in which it is functionally incapable, no longer responsive to antigens. Ways to reverse T cell exhaustion would be very beneficial, and so the research community has made some inroads in understanding the mechanisms of exhaustion, enough to produce proof of concept approaches, such as those involving epigenetic reprogramming, BAFT upregulation, TIGIT knockdown, and various s...
Source: Fight Aging! - November 9, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, November 6th 2023
This study aimed to gather valuable insights from pharmaceutical experts and healthcare practitioners regarding the potential and challenges of translating senolytic drugs for treatment of vascular aging-related disorders. This study employed a qualitative approach by conducting in-depth interviews with healthcare practitioners and pharmaceutical experts. Participants were selected through purposeful sampling. Thematic analysis was used to identify themes from the interview transcripts. A total of six individuals were interviewed, with three being pharmaceutical experts and the remaining three healthcare practitioners.
...
Source: Fight Aging! - November 5, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Towards Senolytic Immunotherapies that Use Cytotoxic T Cells
As researchers here point out, cytotoxic T cells can in principle attack and destroy lingering senescent cells in aged tissues. That they don't do enough of this in old age is clear, but that they are capable of it at all opens the door to finding ways to encourage greater activity. Deciduous Therapeutics runs a development program focused on encouraging a different set of immune cells to kill senescent cells, while engineered T cells equipped with chimeric antigen receptors have been tested in animal models for their ability to kill senescent cells. It is likely that other groups will try a variety of senolytic immunother...
Source: Fight Aging! - November 1, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Towards Inhibition of α-Synuclein Aggregation
We report that αS1-25 inhibits lipid-induced αS aggregation in a dose-dependent manner. αS1-25 functions by binding to lipids to prevent αS binding, with both αS and peptide requiring lipid for inhibition to occur. These findings present a potential mechanistic route for the treatment or prevention of PD. (Source: Fight Aging!)
Source: Fight Aging! - October 18, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, October 16th 2023
In conclusion, a number of studies have shown that CD4+ Treg cells are crucial in the maintenance of peripheral tolerance and have an important role in the control of atherosclerosis-related inflammation. Therefore, Treg cells are a promising target of major research efforts focused on immune-modulating therapies against atherosclerosis. Developing anti-atherosclerotic Treg-based therapies faces challenges. However, rapid progress in genetic, epigenetic, and molecular aspects of cellular immunology gives hope for a fast-track solution.
« Back to Top
Delivering Senolytic Nanoparticles to Atheroscle...
Source: Fight Aging! - October 15, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Adoptive Transfer of Regulatory T Cells as a Way to Treat Atherosclerosis
In conclusion, a number of studies have shown that CD4+ Treg cells are crucial in the maintenance of peripheral tolerance and have an important role in the control of atherosclerosis-related inflammation. Therefore, Treg cells are a promising target of major research efforts focused on immune-modulating therapies against atherosclerosis. Developing anti-atherosclerotic Treg-based therapies faces challenges. However, rapid progress in genetic, epigenetic, and molecular aspects of cellular immunology gives hope for a fast-track solution. (Source: Fight Aging!)
Source: Fight Aging! - October 11, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Microneedle Skin Patch Measures Cancer Biomarkers
Researchers at the Harvard Wyss Institute have developed a technique that lets clinicians to characterize and monitor melanoma. The system involves using a microneedle patch that can draw deep interstitial fluid into itself through a series of penetrating hyaluronic acid needles. The needles can later be dissolved to release the biomarkers into a test tube before analysis, using a highly sensitive technique called Simoa, to detect individual biomarker protein molecules. The Simoa method involves capturing these molecules using an antibody attached to a magnetic bead, which allows the researchers to use magnets to separate ...
Source: Medgadget - September 14, 2023 Category: Medical Devices Authors: Conn Hastings Tags: Dermatology Diagnostics Medicine Oncology harvard wyssinstitute Source Type: blogs
mRNA Immunotherapy Targets Cancer
Researchers at the Mount Sinai Hospital have developed an mRNA-based treatment for cancer. The approach combines the delivery of mRNA therapy in lipid nanoparticles and also involves co-delivering dendritic cells that have also been primed through treatment with lipid-encased mRNA. The technology aims to overcome some of the immune evasive tricks that tumors use to circumvent the immune system, some of which can hamper more traditional immunotherapies. In contrast, this treatment, which the researchers have called CATCH, aims to progress the cancer immunity cycle by modulating the tumor microenvironment to support an anti-...
Source: Medgadget - August 25, 2023 Category: Medical Devices Authors: Conn Hastings Tags: Genetics Medicine Oncology immunotherapy MountSinaiNYC mRNA Immunotherapy Source Type: blogs
Fight Aging! Newsletter, July 31st 2023
In conclusion, an SBP level below 130 mmHg was found to be associated with longevity among older women. The longer SBP was controlled at a level between 110 and 130 mmHg, the higher the survival probability to age 90. Preventing age-related rises in SBP and increasing the time with controlled BP levels constitute important measures for achieving longevity.
« Back to Top (Source: Fight Aging!)
Source: Fight Aging! - July 30, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Donanemab Slows Progression of Earlier, Less Severe Alzheimer's Disease
Several immunotherapies targeting amyloid-β in the brain have now been shown to modestly slow the progression of Alzheimer's disease if applied at an earlier stage of the condition. This is a long way removed from a cure, particularly given the potentially severe side-effects that accompany brain-targeted monoclonal antibody therapies. Alzheimer's is a complicated condition, and it seems clear that removing amyloid-β does too little on its own to reduce pathology in the brain. It is contributing, but it is not the only contribution, or perhaps not even the most important contribution. More will be needed in parallel, suc...
Source: Fight Aging! - July 24, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Why oncology is ripe for digital innovation
In every aspect of our lives, whether it is online banking or shopping, we rely on technology to make things better, more convenient, and more efficient. Yet in health care, and particularly cancer care, that is not the case. Oncology has been revolutionized in recent decades by therapies targeted to specific biomarkers and immunotherapy. Despite
Read more…
Why oncology is ripe for digital innovation originally appeared in KevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - July 18, 2023 Category: General Medicine Authors: Andrew Norden, MD, MPH, MBA Tags: Tech Health IT Oncology/Hematology Source Type: blogs
Should doctors prescribe Leqembi (lecanemab) to women with early Alzheimer ’s Disease? The evidence-based answer is probably No
Welcome to a new edition of SharpBrains e‑newsletter, featuring this time a range of interventions for brain/ cognitive/ mental health plus a few brain teasers to test our perception and cognitive skills.
#1. Should doctors prescribe lecanemab (Leqembi) to women? The answer, given available evidence, is probably No
Huge (and mostly overlooked) red flag regarding newly approved “anti-Alzheimer’s” drugs: “To put it bluntly, if lecanemab doesn’t work in women it would be unethical to supply it to women. Recall this costly immunotherapy comes with substantive risks, including high incidence of ARIA and even death....
Source: SharpBrains - June 28, 2023 Category: Neuroscience Authors: SharpBrains Tags: Brain/ Mental Health SharpBrains Monthly eNewsletter Technology & Innovation ADHD-symptoms Alzheimers-disease Anti-Alzheimer’s Drugs anti-amyloid drugs ARIA Brain Teasers brain teasers for adults cognitive-behavioral-therapy cognit Source Type: blogs
Fight Aging! Newsletter, June 26th 2023
This study explored the association between different cooking fuel types and the risk of cancer and all-cause mortality among seniors constructing Cox regression models. Data were obtained by linking waves of 6, 7, and 8 of the Chinese Longitudinal Healthy Longevity Survey, which included a total of 7,269 participants who were 65 years old and over. Cooking fuels were categorized as either biomass, fossil, or clean fuels. And the effects of switching cooking fuels on death risk were also investigated using Cox regression models.
The results indicate that, compared with the users of clean fuels, individuals using bio...
Source: Fight Aging! - June 25, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
